Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib in Recurrent, Refractory or Progressive Osteosarcoma
NCT05588648Phase 2Recruiting
- Sponsor
- MedPacto
- Start
- May 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vactosertib in osteosarcoma (OS), sponsored by MedPacto. Primary endpoint: Adverse Events at 60 months. Started May 2023; status: recruiting.
02
Drugs
vactosertib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05588648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588648.